1 min read
Japan is one of the world's largest pharmaceutical markets, but many foreign companies underestimate the complexity of its regulatory framework. While Japan is aligned with ICH guidelines, PMDA expectations often differ significantly from those in the US or Europe.
Here are five common mistakes that can delay approvals and increase regulatory risk.
1. Treating Japan as an Extension of FDA or EMA Strategy
Many companies assume that a successful FDA or EMA submission can be replicated for Japan. However, PMDA often expects Japan-specific justification, localized documentation, and additional regulatory considerations.
2. Delaying MAH/DMAH Planning
Without a Marketing Authorization Holder (MAH) or Designated Marketing Authorization Holder (DMAH), medicinal products cannot be marketed in Japan. Late planning often creates avoidable submission delays.
3. Underestimating CMC Localization Requirements
Japan places significant emphasis on Chemistry, Manufacturing, and Controls (CMC) data. Global dossiers frequently require adaptation to meet PMDA expectations and local review practices.
4. Failing to Engage PMDA Early
PMDA consultations can provide valuable feedback on development, clinical, and CMC strategies. Companies that delay engagement often encounter unexpected review questions later in the process.
5. Ignoring Post-Approval Obligations
Approval is only the beginning. PMS, RMP, GPSP, and GVP requirements continue throughout the product lifecycle and should be incorporated into regulatory planning from the outset.
Success in Japan requires more than a strong dossier—it requires a Japan-specific regulatory strategy.
Freyr Solutions helps pharmaceutical and biotech companies navigate PMDA requirements through regulatory strategy, MAH/DMAH support, CTD/eCTD submissions, lifecycle management, and post-marketing compliance.
Partner with Freyr to accelerate your path to successful market entry in Japan.